{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T23:02:53Z","timestamp":1767481373505,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"DOI":"10.7759\/cureus.100711","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T23:01:27Z","timestamp":1767481287000},"source":"Crossref","is-referenced-by-count":0,"title":["Polyclonal Hypergammaglobulinemia in Severe Hidradenitis Suppurativa"],"prefix":"10.7759","author":[{"given":"Cristina  P","family":"Gerena-Maldonado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Sadurn\u00ed-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo S","family":"Caussade-Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Martes-Villalobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15958","article-title":"Polyclonal hyperglobulinaemia and elevated acute-phase reactants in hidradenitis suppurativa","volume":"178","author":"Hoffman LK","year":"2018","unstructured":"Hoffman LK, Ghias MH, Cohen SR, Lowes MA. Polyclonal hyperglobulinaemia and elevated acute-phase reactants in hidradenitis suppurativa. Br J Dermatol. 2018, 178:e134-5. 10.1111\/bjd.15958","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14789","article-title":"Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa","volume":"59","author":"Marzuillo P","year":"2020","unstructured":"Marzuillo P, Caiazzo R, Coppola C, et al.. Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa. Int J Dermatol. 2020, 59:e201-3. 10.1111\/ijd.14789","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S503199","article-title":"Hypergammaglobulinemia in hidradenitis suppurativa patients: a new emerging association","volume":"18","author":"Martora F","year":"2025","unstructured":"Martora F, Battista T, Giordano A, Potestio L, Megna M. Hypergammaglobulinemia in hidradenitis suppurativa patients: a new emerging association. Clin Cosmet Investig Dermatol. 2025, 18:1-5. 10.2147\/CCID.S503199","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan A","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al.. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019, 81:76-90. 10.1016\/j.jaad.2019.02.067","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick J","year":"2025","unstructured":"Rastrick J, Edwards H, Ferecsk\u00f3 AS, Le Friec G, Manghera A, Page M, Shaw S. The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br J Dermatol. 2025, 192:660-71. 10.1093\/bjd\/ljae442","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak L","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?. Acta Derm Venereol. 2009, 89:601-3. 10.2340\/00015555-0749","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2017.65626","article-title":"Increased serum interleukin-6 levels in patients with hidradenitis suppurativa","volume":"34","author":"Xu H","year":"2017","unstructured":"Xu H, Xiao X, He Y, et al.. Increased serum interleukin-6 levels in patients with hidradenitis suppurativa. Postepy Dermatol Alergol. 2017, 34:82-4. 10.5114\/ada.2017.65626","journal-title":"Postepy Dermatol Alergol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter CA","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015, 16:448-57. 10.1038\/ni.3153","journal-title":"Nat Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting DM","year":"2006","unstructured":"Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006, 108:3204-9. 10.1182\/blood-2006-06-027631","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02559-9","article-title":"Anemia in patients with hidradenitis suppurativa: a systematic review with meta-analysis","volume":"315","author":"Revankar R","year":"2023","unstructured":"Revankar R, Rojas M, Walsh S, Patel H, Revankar N, Han J, Parameswaran A. Anemia in patients with hidradenitis suppurativa: a systematic review with meta-analysis. Arch Dermatol Res. 2023, 315:1639-48. 10.1007\/s00403-023-02559-9","journal-title":"Arch Dermatol Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213800","article-title":"Serum immunoglobulin G is a marker of hidradenitis suppurativa severity","volume":"23","author":"Mintoff D","year":"2022","unstructured":"Mintoff D, Borg I, Pace NP. Serum immunoglobulin G is a marker of hidradenitis suppurativa severity. Int J Mol Sci. 2022, 23:13800. 10.3390\/ijms232213800","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1471226","article-title":"IgG4 serologic elevation in a patient with severe hidradenitis suppurativa: a case report and review of the literature","volume":"11","author":"Gauger AJ","year":"2024","unstructured":"Gauger AJ, Fritz M, Burgin CB. IgG4 serologic elevation in a patient with severe hidradenitis suppurativa: a case report and review of the literature. Front Med (Lausanne). 2024, 11:1471226. 10.3389\/fmed.2024.1471226","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard DC","year":"2012","unstructured":"van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012, 23:284-9. 10.3109\/09546634.2011.571657","journal-title":"J Dermatolog Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051351","article-title":"Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis","volume":"15","author":"Tsai YC","year":"2023","unstructured":"Tsai YC, Hung CY, Tsai TF. Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis. Pharmaceutics. 2023, 15:1351. 10.3390\/pharmaceutics15051351","journal-title":"Pharmaceutics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study","volume":"17","author":"Martora F","year":"2024","unstructured":"Martora F, Marasca C, Cacciapuoti S, et al.. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study. Clin Cosmet Investig Dermatol. 2024, 17:159-66. 10.2147\/CCID.S449367","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445392-polyclonal-hypergammaglobulinemia-in-severe-hidradenitis-suppurativa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T23:01:27Z","timestamp":1767481287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445392-polyclonal-hypergammaglobulinemia-in-severe-hidradenitis-suppurativa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.100711","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,3]]}}}